Depot Medroxyprogesterone Injection Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

$ PRICE - $ 3,000.00$ 8,900.00

Depot Medroxyprogesterone Injection Market By Type (Prescriptions & Generic Prescriptions), By End User (Hospital, Pharmacy, & Others), By Application (Contraceptive, Hormone Replacement Therapy, Treatment of Endometriosis, and Others), and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The depot medroxyprogesterone injection market is valued at USD 800.0 million in 2021 and is poised to grow at a significant CAGR of 4.0% over 2022–2028. The injectable progestin-only contraceptive depot medroxyprogesterone acetate (DMPA, often known as Depo-Provera) provides very effective, discreet, three-month reversible contraception. DMPA removes the necessity for daily user activity, action close to sexual intercourse, and partner collaboration. By legalizing the use of injectable contraceptives, developing countries are focusing on lowering infant and mother mortality rates. For example, Haryana was the first state in India to implement the usage of injectable contraceptives. The project would start in nine districts across the state, with the injectable available for free at all district hospitals, primary health centers, and community health centers. The United Kingdom authorities authorized Sayana Press in 2015, a three-month progestin-only injectable contraception. The governmental and private partners declared at the London Summit that they would deliver around 12 million doses of Sayana Press to the world’s poorest countries by 2020. Injections have traditionally been a popular method of contraception in Sub-Saharan Africa, and the introduction of the Sayana Press injection and Uniject device is expected to increase demand. The all-in-one prefilled injectable device increases access through non-clinical channels while improving safety. The unmet need for contraception remains high. An estimated 225 million women in developing countries would like to delay or prevent pregnancy but are not using any method of contraception. Common reasons include difficulty traveling to health facilities, social barriers, and lack of knowledge about available contraceptive methods. Developing countries are home to more significant population density; it is imperative that the governments and local organizations need to play a pivotal role in creating awareness about family planning, thereby reducing the number of childbirths and population. This could potentially create a market opportunity for the players who offer contraceptive injections at affordable prices. Moreover, the growing demographic dividend in these regions and an increase in fertility rate will positively impact the contraceptive markets in general. It may present a lucrative opportunity for market players with greater market penetration and access to injectable formulations.

Recent Market Developments:

In January 2019, Drug firm Cipla received the final nod from the US health regulator for its Medroxyprogesterone injectable to prevent pregnancy. The company has received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Medroxyprogesterone injectable at 150mg/mL.

Depot Medroxyprogesterone Injection Market

MARKET SUMMARY
-
4.0% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 4.0%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Depot Medroxyprogesterone Injection Market

  • The Depot Medroxyprogesterone Injection Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The Depot Medroxyprogesterone Injection Market is segmented based on type, end-user, application, and geography.
Key Players
  • Pfizer Inc.
  • Fangtong Pharma. Co. Ltd
  • Gador S.A.
  • Sigma-Aldrich Co. LLC.
  • Teva Pharmaceutical Industries Ltd.
Depot Medroxyprogesterone Injection Market

Dynamics

The growing demand for birth control measures and government attempts to raise awareness about various contraceptive methods are driving the market for Depot Medroxyprogesterone Injection. Various forecasting projects are underway to assess better the demand for Depot medroxyprogesterone acetate (DMPA) as a birth control method. For instance, The Concept Foundation hired the William Davidson Institute (WDI) in January 2015 to research DMPA demand in low- and middle-income nations. Manufacturers are now attempting to produce a subcutaneous low-dose injectable of medroxyprogesterone acetate to reduce some weight gain and metabolic side effects. On the other hand, DMPA has long been connected to various health problems, including osteoporosis, breast cancer, and a delayed return of fertility. In addition, long-term use of DPMA may result in a loss of bone mineral density; these factors restrain the depot medroxyprogesterone injection market.


North-America Got Significant Share

Depot Medroxyprogesterone Injection Market

The depot medroxyprogesterone injection market in North America will likely hold the highest revenue share in 2022. In the following years, it is predicted to increase rapidly. North America has dominated the depot medroxyprogesterone injection market due to significant market players, technological advances, and research investments. Furthermore, numerous firms are attempting to join the call for medroxyprogesterone acetate with innovative technology and improved efficacy.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Findings of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2016-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Depot Medroxyprogesterone Injection Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Company Profile

  • Pfizer Inc.
  • Fangtong Pharma. Co. Ltd
  • Gador S.A.
  • Sigma-Aldrich Co. LLC.
  • Teva Pharmaceutical Industries Ltd.
  • Greenstone LLC
  • Serum Internation Ltd.
  • West-Coast Pharmaceutical
  • Arrow Pharma Group,
  • Zuche Pharmaceuticals Pvt. Ltd.

Description

The depot medroxyprogesterone injection market is valued at USD 800.0 million in 2021 and is poised to grow at a significant CAGR of 4.0% over 2022–2028. The injectable progestin-only contraceptive depot medroxyprogesterone acetate (DMPA, often known as Depo-Provera) provides very effective, discreet, three-month reversible contraception. DMPA removes the necessity for daily user activity, action close to sexual intercourse, and partner collaboration. By legalizing the use of injectable contraceptives, developing countries are focusing on lowering infant and mother mortality rates. For example, Haryana was the first state in India to implement the usage of injectable contraceptives. The project would start in nine districts across the state, with the injectable available for free at all district hospitals, primary health centers, and community health centers. The United Kingdom authorities authorized Sayana Press in 2015, a three-month progestin-only injectable contraception. The governmental and private partners declared at the London Summit that they would deliver around 12 million doses of Sayana Press to the world’s poorest countries by 2020. Injections have traditionally been a popular method of contraception in Sub-Saharan Africa, and the introduction of the Sayana Press injection and Uniject device is expected to increase demand. The all-in-one prefilled injectable device increases access through non-clinical channels while improving safety. The unmet need for contraception remains high. An estimated 225 million women in developing countries would like to delay or prevent pregnancy but are not using any method of contraception. Common reasons include difficulty traveling to health facilities, social barriers, and lack of knowledge about available contraceptive methods. Developing countries are home to more significant population density; it is imperative that the governments and local organizations need to play a pivotal role in creating awareness about family planning, thereby reducing the number of childbirths and population. This could potentially create a market opportunity for the players who offer contraceptive injections at affordable prices. Moreover, the growing demographic dividend in these regions and an increase in fertility rate will positively impact the contraceptive markets in general. It may present a lucrative opportunity for market players with greater market penetration and access to injectable formulations.

Recent Market Developments:

In January 2019, Drug firm Cipla received the final nod from the US health regulator for its Medroxyprogesterone injectable to prevent pregnancy. The company has received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Medroxyprogesterone injectable at 150mg/mL.

Reviews

There are no reviews yet.

Be the first to review “Depot Medroxyprogesterone Injection Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)”

Your email address will not be published. Required fields are marked *

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX